Ace the CRNI Challenge 2026 – Infuse Your Career with Success!

Intravenous immunoglobulin (IVIG) is a therapy that provides antibodies to help the immune system function more effectively. One of the primary uses of IVIG is in treating immune thrombocytopenic purpura (ITP), a condition where the immune system mistakenly attacks and destroys platelets, leading to low platelet counts and increasing the risk of bleeding.

IVIG works in ITP by supplying a large pool of antibodies, which may help modulate the immune response. It assists in raising the platelet count temporarily by reducing the immune-mediated destruction of platelets. This rise in platelet levels can improve bleeding symptoms and is often seen within a few days after administration. Given the specific role of IVIG in influencing platelet dynamics in ITP, it makes clear why this option is the correct answer regarding the condition that IVIG helps improve.

The other options are not accurate in the context of IVIG treatment. For example, IVIG does not have a known effect on white blood cell counts in leukemia, respiratory function in asthma, or blood sugar levels in diabetes, where other targeted therapies and management strategies are typically utilized.